AR129501A2 - FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN - Google Patents
FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓNInfo
- Publication number
- AR129501A2 AR129501A2 ARP230101391A ARP230101391A AR129501A2 AR 129501 A2 AR129501 A2 AR 129501A2 AR P230101391 A ARP230101391 A AR P230101391A AR P230101391 A ARP230101391 A AR P230101391A AR 129501 A2 AR129501 A2 AR 129501A2
- Authority
- AR
- Argentina
- Prior art keywords
- microns
- particles
- anticholinergic
- dry powder
- corticosteroid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000001078 anti-cholinergic effect Effects 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000003246 corticosteroid Substances 0.000 title abstract 3
- 239000002245 particle Substances 0.000 abstract 4
- 239000000843 powder Substances 0.000 abstract 3
- 239000011362 coarse particle Substances 0.000 abstract 2
- 229940112141 dry powder inhaler Drugs 0.000 abstract 2
- 239000010419 fine particle Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 abstract 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- 229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 abstract 1
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Reciprocating Pumps (AREA)
Abstract
Formulaciones en polvo seco para inhalación que comprenden una combinación de un anticolinérgico, un agonista de adrenoceptor b₂ de acción prolongada y un corticosteroide, proceso de preparación y usos terapéuticos de las mismas. Reivindicación 1: Una formulación en polvo seco para usar en un inhalador en polvo seco (DPI) caracterizada porque comprende: a) una fracción de partículas finas que consiste en una mezcla, que se prepara por comezclado en un aparato de alta energía durante un período de menos de 20 minutos, entre 90 y 99,5 por ciento en peso de partículas micronizadas de un excipiente fisiológicamente aceptable y entre 0,5 y 10 por ciento en peso de estereato de magnesio, en donde al menos el 90% de todas dichas partículas tiene un diámetro de volumen menor que 15 micrones, preferentemente menor que 12 micrones, y el diámetro mediano de volumen de dichas partículas está comprendido entre 3 y 7 micrones, preferentemente entre 4 y 6 micrones; b) una fracción de partículas gruesas que consiste en un excipiente fisiológicamente aceptable que tiene un diámetro mediano de masa igual o mayor que 100 micrones, en donde la proporción entre las partículas finas y las partículas gruesas es entre 1:99 y 30:70 por ciento en peso, y c) partículas micronizadas de un anticolinérgico, un corticosteroide para inhalación (ICS), y un agonista de b₂ de acción prolongada (LABA) como principios activos. Reivindicación 3: La formulación en polvo de acuerdo a la reivindicación 1 o 2, caracterizada porque el LABA es formoterol fumarato dihidratado, el ICS es dipropionato de beclometasona y el anticolinérgico es bromuro de glicopirronio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176114 | 2013-07-11 | ||
| EP13194763 | 2013-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129501A2 true AR129501A2 (es) | 2024-09-04 |
Family
ID=51292914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101391A AR129501A2 (es) | 2013-07-11 | 2023-06-01 | FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9402825B2 (es) |
| EP (3) | EP3569222B1 (es) |
| JP (1) | JP6426167B2 (es) |
| KR (2) | KR102275904B1 (es) |
| CN (1) | CN105338960B (es) |
| AR (1) | AR129501A2 (es) |
| AU (1) | AU2014289185B2 (es) |
| BR (1) | BR112015030914B1 (es) |
| CA (1) | CA2917752C (es) |
| CL (1) | CL2016000028A1 (es) |
| CY (2) | CY1120806T1 (es) |
| DK (3) | DK3409270T3 (es) |
| EA (1) | EA029125B1 (es) |
| ES (3) | ES2699986T3 (es) |
| FI (1) | FI3569222T3 (es) |
| GE (2) | GEP20186853B (es) |
| HR (3) | HRP20241300T1 (es) |
| HU (3) | HUE068270T2 (es) |
| IL (1) | IL243507A0 (es) |
| LT (3) | LT3569222T (es) |
| MX (1) | MX2016000290A (es) |
| MY (1) | MY176176A (es) |
| NZ (1) | NZ715797A (es) |
| PE (2) | PE20160372A1 (es) |
| PH (1) | PH12016500043B1 (es) |
| PL (3) | PL3019153T3 (es) |
| PT (1) | PT3019153T (es) |
| RS (3) | RS57799B1 (es) |
| SA (1) | SA516370373B1 (es) |
| SG (1) | SG11201600110RA (es) |
| SI (3) | SI3569222T1 (es) |
| TN (1) | TN2016000007A1 (es) |
| TW (1) | TWI642450B (es) |
| UA (1) | UA116907C2 (es) |
| WO (1) | WO2015004243A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2515855T6 (da) * | 2009-12-23 | 2023-06-06 | Chiesi Farm Spa | Kombinationsterapi til COPD |
| HUE060421T2 (hu) * | 2012-01-25 | 2023-02-28 | Chiesi Farm Spa | Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra |
| ES2699986T3 (es) * | 2013-07-11 | 2019-02-13 | Chiesi Farm Spa | Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
| JP6600961B2 (ja) * | 2015-03-30 | 2019-11-06 | ブラザー工業株式会社 | 表示制御装置、表示制御方法及び記憶媒体 |
| US20180147161A1 (en) * | 2015-05-01 | 2018-05-31 | Board Of Regents, The University Of Texas System | Multidrug brittle matrix compositions |
| AR106687A1 (es) * | 2015-11-16 | 2018-02-07 | Chiesi Farm Spa | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO |
| LT3377108T (lt) | 2015-11-16 | 2020-07-10 | Chiesi Farmaceutici S.P.A. | Inhaliacinių miltelių kompozicijos, apimančios anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, paruošimo būdas |
| CA3062126C (en) | 2016-11-10 | 2021-04-27 | Medisca Pharmaceutique Inc. | Container assembly and adapter therefor |
| CN110582269B (zh) * | 2017-05-11 | 2023-02-28 | 奇斯药制品公司 | 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法 |
| US10350164B2 (en) | 2017-05-11 | 2019-07-16 | Chiesi Farmaceutici S.P.A. | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| CN109200034A (zh) * | 2017-06-30 | 2019-01-15 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的组合物及其制备方法 |
| WO2019060595A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| AU2020356243A1 (en) * | 2019-09-24 | 2022-03-24 | Chiesi Farmaceutici S.P.A. | Novel carrier particles for dry powder formulations for inhalation |
| US12029709B2 (en) * | 2022-08-11 | 2024-07-09 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ511527A (en) * | 1998-11-13 | 2002-10-25 | Jago Res A | Dry powder for inhalation |
| US20070212422A1 (en) * | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| JP5698423B2 (ja) * | 2000-06-27 | 2015-04-08 | ベクトゥラ・リミテッド | 医薬組成物で使用するための粒子の製造法 |
| PT2283817T (pt) * | 2000-11-30 | 2016-08-22 | Vectura Ltd | Método de fabrico de partículas para utilização numa composição farmacêutica |
| EP1658872B2 (en) | 2002-07-31 | 2019-08-21 | CHIESI FARMACEUTICI S.p.A. | Powder inhaler |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| WO2011076841A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| DK2515855T6 (da) | 2009-12-23 | 2023-06-06 | Chiesi Farm Spa | Kombinationsterapi til COPD |
| TR201000681A2 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | İnhalasyon yoluyla alınan kuru toz formülasyonları. |
| PL2552424T3 (pl) | 2010-04-01 | 2018-10-31 | Chiesi Farmaceutici S.P.A. | Sposób wytwarzania cząstek nośnika do suchych proszków do inhalacji |
| HRP20180488T1 (hr) * | 2010-04-21 | 2018-07-13 | Chiesi Farmaceutici S.P.A. | Postupak priprave čestica sa smanjenim elektrostatičkim nabojem |
| CA2803418A1 (en) * | 2010-06-22 | 2011-12-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising an antimuscarinic drug |
| HUE060421T2 (hu) * | 2012-01-25 | 2023-02-28 | Chiesi Farm Spa | Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| ES2699986T3 (es) * | 2013-07-11 | 2019-02-13 | Chiesi Farm Spa | Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación |
-
2014
- 2014-07-10 ES ES14747855T patent/ES2699986T3/es active Active
- 2014-07-10 TN TN2016000007A patent/TN2016000007A1/en unknown
- 2014-07-10 GE GEAP201414032A patent/GEP20186853B/en unknown
- 2014-07-10 ES ES19182016T patent/ES2986128T3/es active Active
- 2014-07-10 CN CN201480037266.1A patent/CN105338960B/zh active Active
- 2014-07-10 RS RS20181254A patent/RS57799B1/sr unknown
- 2014-07-10 PL PL14747855T patent/PL3019153T3/pl unknown
- 2014-07-10 GE GEAP201814032A patent/GEAP201814032A/en unknown
- 2014-07-10 UA UAA201600204A patent/UA116907C2/uk unknown
- 2014-07-10 HR HRP20241300TT patent/HRP20241300T1/hr unknown
- 2014-07-10 DK DK18178893.6T patent/DK3409270T3/da active
- 2014-07-10 FI FIEP19182016.6T patent/FI3569222T3/fi active
- 2014-07-10 EP EP19182016.6A patent/EP3569222B1/en active Active
- 2014-07-10 CA CA2917752A patent/CA2917752C/en active Active
- 2014-07-10 ES ES18178893T patent/ES2867552T3/es active Active
- 2014-07-10 HU HUE19182016A patent/HUE068270T2/hu unknown
- 2014-07-10 NZ NZ715797A patent/NZ715797A/en unknown
- 2014-07-10 KR KR1020217018070A patent/KR102275904B1/ko active Active
- 2014-07-10 SI SI201432094T patent/SI3569222T1/sl unknown
- 2014-07-10 RS RS20241002A patent/RS65951B1/sr unknown
- 2014-07-10 EA EA201690006A patent/EA029125B1/ru unknown
- 2014-07-10 KR KR1020167000719A patent/KR20160029797A/ko not_active Ceased
- 2014-07-10 BR BR112015030914-3A patent/BR112015030914B1/pt active IP Right Grant
- 2014-07-10 LT LTEP19182016.6T patent/LT3569222T/lt unknown
- 2014-07-10 PE PE2016000025A patent/PE20160372A1/es unknown
- 2014-07-10 EP EP18178893.6A patent/EP3409270B1/en active Active
- 2014-07-10 HU HUE14747855A patent/HUE039827T2/hu unknown
- 2014-07-10 JP JP2016524826A patent/JP6426167B2/ja active Active
- 2014-07-10 PT PT14747855T patent/PT3019153T/pt unknown
- 2014-07-10 TW TW103123763A patent/TWI642450B/zh active
- 2014-07-10 SG SG11201600110RA patent/SG11201600110RA/en unknown
- 2014-07-10 LT LTEP14747855.6T patent/LT3019153T/lt unknown
- 2014-07-10 HR HRP20182008TT patent/HRP20182008T1/hr unknown
- 2014-07-10 RS RS20210320A patent/RS61652B1/sr unknown
- 2014-07-10 SI SI201430976T patent/SI3019153T1/sl unknown
- 2014-07-10 WO PCT/EP2014/064824 patent/WO2015004243A1/en not_active Ceased
- 2014-07-10 PL PL18178893T patent/PL3409270T3/pl unknown
- 2014-07-10 PE PE2021000280A patent/PE20212110A1/es unknown
- 2014-07-10 MX MX2016000290A patent/MX2016000290A/es active IP Right Grant
- 2014-07-10 DK DK14747855.6T patent/DK3019153T3/en active
- 2014-07-10 HU HUE18178893A patent/HUE053957T2/hu unknown
- 2014-07-10 LT LTEP18178893.6T patent/LT3409270T/lt unknown
- 2014-07-10 SI SI201431806T patent/SI3409270T1/sl unknown
- 2014-07-10 PL PL19182016.6T patent/PL3569222T3/pl unknown
- 2014-07-10 EP EP14747855.6A patent/EP3019153B1/en active Active
- 2014-07-10 AU AU2014289185A patent/AU2014289185B2/en active Active
- 2014-07-10 MY MYPI2016000023A patent/MY176176A/en unknown
- 2014-07-10 US US14/327,920 patent/US9402825B2/en active Active
- 2014-07-10 DK DK19182016.6T patent/DK3569222T3/da active
-
2016
- 2016-01-07 IL IL243507A patent/IL243507A0/en active IP Right Grant
- 2016-01-07 PH PH12016500043A patent/PH12016500043B1/en unknown
- 2016-01-07 SA SA516370373A patent/SA516370373B1/ar unknown
- 2016-01-08 CL CL2016000028A patent/CL2016000028A1/es unknown
- 2016-05-20 US US15/160,593 patent/US9808422B2/en active Active
-
2018
- 2018-11-01 CY CY181101132T patent/CY1120806T1/el unknown
-
2021
- 2021-03-12 CY CY20211100219T patent/CY1123937T1/el unknown
- 2021-05-06 HR HRP20210704TT patent/HRP20210704T1/hr unknown
-
2023
- 2023-06-01 AR ARP230101391A patent/AR129501A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129501A2 (es) | FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN | |
| PE20141703A1 (es) | Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion | |
| RU2014140539A (ru) | Агрегированные частицы | |
| AR085120A1 (es) | Formulaciones de particulas en polvo seco que contienen dos o mas ingredientes activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vias respiratorias | |
| PE20011227A1 (es) | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros | |
| CO6640319A2 (es) | Formulación en polvo seca que comprende una droga antimuscarínica | |
| MX382192B (es) | Composiciones de canabinoide y usos. | |
| AR049010A1 (es) | Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| WO2008084312A3 (en) | Micronised particles of low-dosage strength active agents for powder formulations for inhalation | |
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| GEAP202014783A (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
| GT201300144A (es) | Composiciones farmaceuticas | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| BR112015020443A8 (pt) | formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica | |
| AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
| CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| BR112015027247A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas | |
| MX2015011624A (es) | Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras. | |
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| AR096878A1 (es) | FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN | |
| AR086248A1 (es) | Formulacion en forma de suspension mejorada de un corticosteroide que puede administrarse por inhalacion | |
| BR112012018696A2 (pt) | composição farmacêutica com atividade antiobesidade compreendendo uma pré-mistura de orlistat puro e processo de preparação |